Market Place
Sourcing Support
Enterprise Therapeutics Publishes on ETD001 for Cystic Fibrosis
19 Nov 2024 //
BUSINESSWIRE
Enterprise Therapeutics Gets Rare Pediatric Designation
26 Sep 2024 //
BUSINESSWIRE
Enterprise Therapeutics Doses First CF Patient In ETD001 Phase 2 Trial
23 Jul 2024 //
BUSINESSWIRE
Enterprise Therapeutics Publishes Preclinical Profile Of ETD001
12 Jun 2024 //
BUSINESSWIRE
Enterprise Therapeutics Closes £26 million Series B Follow-on Financing
30 Jan 2024 //
BUSINESSWIRE
Enterprise Therapeutics doses first subjects in Phase I trial with ETD001
14 Jun 2021 //
BUSINESSWIRE
Enterprise Therapeutics doses first subjects in Phase I trial for ETD001
14 Jun 2021 //
BUSINESSWIRE
Roche acquires Enterprise Therapeutics’ potentiator portfolio
07 Oct 2020 //
BIOSPACE
Forbion Portfolio Company, Enterprise Therapeutics’ First-in-Class TMEM16A
07 Oct 2020 //
BUSINESSWIRE
Enterprise Therapeutics’ TMEM16A potentiator program acquired by Roche
06 Oct 2020 //
BUSINESSWIRE
Enterprise Doses First Subjects in Ph 1 Trial for 1ST Cystic Fibrosis ETD002
17 Aug 2020 //
BUSINESSWIRE
Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer
10 Feb 2020 //
BUSINESS WIRE
Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach
08 Jan 2020 //
BUSINESS WIRE
Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach
08 Jan 2020 //
BUSINESS WIRE
Enterprise Therapeutics Publishes Paper on Novel Therapeutic Approach
07 Jan 2020 //
BUSINESS WIRE
Enterprise Therapeutics Awarded up to £5.7M from Cystic Fibrosis Foundation
16 Oct 2019 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.